Karen Mactier

Karen Mactier serves as an Honorary Clinical Lecturer within the School of Cancer Sciences at the University of Glasgow, maintaining a research affiliation with CRUK Scotland at Garscube Estate in Glasgow. Her position bridges clinical oncology practice with academic research in the Scottish healthcare context, focusing on translational cancer studies through institutional collaboration with the university's cancer research infrastructure.

Her research centers on aggressive and rare malignancies including glioblastoma, head/neck cancers, and thyroid cancers, with specialized emphasis on uterine sarcoma outcomes and immunotherapy applications. The TOURISM study demonstrates her methodological approach to decade-long retrospective analyses of cancer treatment patterns, while her work on pembrolizumab explores real-world implementation challenges of novel therapies within regional healthcare systems. This research portfolio reveals a consistent focus on treatment accessibility, therapeutic efficacy, and regional disparities in oncology care across the UK.

Recent publications indicate growing scholarly attention to immunotherapy combinations in head/neck cancers and rare sarcoma management, reflecting contemporary shifts toward personalized medicine in oncology. Her work prioritizes practical clinical questions through real-world evidence generation rather than basic science investigations, with strong regional focus on Scottish and UK-wide cancer services.

No scientific awards or major honors were documented in available sources.

Information regarding student mentorship, grant funding, or formal advising roles was not provided in the source materials.

No dedicated laboratories or research teams under Dr. Mactier's leadership were specified in the institutional profile.